|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...3435363738394041424344...4647» |
- ||| GSK2981710 / GSK
Enrollment open: Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects (clinicaltrials.gov) - Dec 5, 2012
P1, N=88, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting
- ||| Enrollment change: iCare Stress Management e-Training for Dementia Family Caregivers (clinicaltrials.gov) - Dec 4, 2012
P2, N=150, Completed, Sponsor: Photozig, Inc.
Not yet recruiting --> Recruiting N=120 --> 150
- Clinical: PRAXALIM: Conservation of Praxis in the Food and Alzheimer Disease (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=32, Recruiting, Sponsor: University Hospital, Limoges
- |||| Trial completion: iCare Stress Management e-Training for Dementia Family Caregivers (clinicaltrials.gov) - Dec 4, 2012
P2, N=150, Completed, Sponsor: Photozig, Inc.
N=120 --> 150 Active, not recruiting --> Completed
- donepezil / Generic mfg.
Trial termination: Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=18, Terminated, Sponsor: Pfizer
Recruiting --> Terminated; The study was terminated because of slow enrollment. The decision to terminate the trial was not based on any safety or efficacy concerns.
- donepezil / Generic mfg.
Enrollment change: Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=18, Terminated, Sponsor: Pfizer
The decision to terminate the trial was not based on any safety or efficacy concerns. N=32 --> 18
- |||||| verubecestat (MK-8931) / Merck (MSD)
Enrollment open: EPOCH: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (clinicaltrials.gov) - Dec 3, 2012
P2/3, N=1960, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=32 --> 18 Not yet recruiting --> Recruiting
- Enrollment open: Prevention of Delirium After Bone Marrow Transplantation (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: ASPIS: Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke (clinicaltrials.gov) - Dec 3, 2012
P4, N=200, Active, not recruiting, Sponsor: Danube University Krems
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- tricaprilin (AC-1204) / Cerecin
Trial withdrawal: AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) (clinicaltrials.gov) - Dec 2, 2012
P2/3, N=0, Withdrawn, Sponsor: Accera, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- tricaprilin (AC-1204) / Cerecin
Enrollment change: AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) (clinicaltrials.gov) - Dec 2, 2012
P2/3, N=0, Withdrawn, Sponsor: Accera, Inc.
Not yet recruiting --> Withdrawn N=400 --> 0
- |||||||||| verubecestat (MK-8931) / Merck (MSD)
New P2/3 trial: EPOCH: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (clinicaltrials.gov) - Nov 29, 2012
P2/3, N=1960, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- atomoxetine / Generic mfg.
New P2 trial: Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) (clinicaltrials.gov) - Nov 28, 2012
P2, N=30, Recruiting, Sponsor: Medical University of South Carolina
- Clinical: Living With Frontotemporal Dementia (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=40, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
- Trial completion: CREST-X: Creatine Safety & Tolerability in Huntington's Disease (clinicaltrials.gov) - Nov 27, 2012
P2, N=10, Completed, Sponsor: Massachusetts General Hospital
N=400 --> 0 Active, not recruiting --> Completed
- ||||| galantamine hydrobromide / Generic mfg.
New P4 trial: A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease (clinicaltrials.gov) - Nov 25, 2012
P4, N=1882, Completed, Sponsor: Janssen Korea, Ltd., Korea
- itanapraced (CHF-5074) / CereSpir
Biomarker, Trial withdrawal: CT05: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment (clinicaltrials.gov) - Nov 19, 2012
P2, N=0, Withdrawn, Sponsor: Chiesi Pharmaceuticals Inc.
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- itanapraced (CHF-5074) / CereSpir
Biomarker, Enrollment change: CT05: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment (clinicaltrials.gov) - Nov 19, 2012
P2, N=0, Withdrawn, Sponsor: Chiesi Pharmaceuticals Inc.
Not yet recruiting --> Withdrawn N=261 --> 0
- verubecestat (MK-8931) / Merck (MSD)
Enrollment change: A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535]) (clinicaltrials.gov) - Nov 19, 2012
P1, N=12, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=261 --> 0 N=36 --> 12
- | verubecestat (MK-8931) / Merck (MSD)
Trial completion: A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535]) (clinicaltrials.gov) - Nov 19, 2012
P1, N=12, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=36 --> 12 Active, not recruiting --> Completed
- Enrollment change: Randomized Trial of a Nutritional Supplement in Alzheimer's Disease (clinicaltrials.gov) - Nov 12, 2012
P3, N=27, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=60 --> 27
- |||| selisistat (SEN-196) / AOP Orphan Pharma
Trial completion: A Phase II Safety and Tolerability Study With SEN0014196 (clinicaltrials.gov) - Nov 12, 2012
P2, N=144, Completed, Sponsor: Siena Biotech S.p.A.
N=60 --> 27 Active, not recruiting --> Completed
- Trial completion: Randomized Trial of a Nutritional Supplement in Alzheimer's Disease (clinicaltrials.gov) - Nov 12, 2012
P3, N=27, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Effects of Exercise Training in Patients With Mild Cognitive Impairment (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=60, Completed, Sponsor: National Taiwan University Hospital
- Enrollment closed: A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- haloperidol / Generic mfg.
Trial initiation date: HARPOON: Haloperidol Prophylaxis in Older Emergency Department Patients (clinicaltrials.gov) - Nov 6, 2012
P4, N=600, Recruiting, Sponsor: VU University Medical Center
Recruiting --> Active, not recruiting Initiation date: Jun 2012 --> Nov 2012
- itanapraced (CHF-5074) / CereSpir
Biomarker, New P2 trial: CT05: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment (clinicaltrials.gov) - Nov 6, 2012
P2, N=0, Withdrawn, Sponsor: Chiesi Pharmaceuticals Inc.
- haloperidol / Generic mfg.
Enrollment open: HARPOON: Haloperidol Prophylaxis in Older Emergency Department Patients (clinicaltrials.gov) - Nov 6, 2012
P4, N=600, Recruiting, Sponsor: VU University Medical Center
Initiation date: Jun 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- Enrollment change: Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=154, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting N=90 --> 154
- Trial completion: Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=154, Completed, Sponsor: Yale University
N=90 --> 154 Recruiting --> Completed
- ramelteon / Generic mfg.
Trial withdrawal: Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment open: Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=150, Recruiting, Sponsor: Charite University, Berlin, Germany
Terminated --> Withdrawn Not yet recruiting --> Recruiting
- Trial initiation date: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - Oct 31, 2012
P4, N=100, Recruiting, Sponsor: Gelderse Vallei Hospital
Not yet recruiting --> Recruiting Initiation date: Sep 2011 --> Jun 2012
- Enrollment open: Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs) (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=416, Recruiting, Sponsor: University of Washington
Initiation date: Sep 2011 --> Jun 2012 Not yet recruiting --> Recruiting
- Enrollment open: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - Oct 31, 2012
P4, N=100, Recruiting, Sponsor: Gelderse Vallei Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Xefo (lornoxicam) - Old API Wind / down, Takeda
Trial termination: Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease. (clinicaltrials.gov) - Oct 29, 2012
P2, N=219, Terminated, Sponsor: JSW Lifesciences
Not yet recruiting --> Recruiting Recruiting --> Terminated; Lack of Efficacy
- | elenbecestat (E2609) / Eisai, Biogen
New P1 trial: An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption (clinicaltrials.gov) - Oct 28, 2012
P1, N=18, Completed, Sponsor: Eisai Inc.
- Enbrel (etanercept) / Pfizer, Amgen
New P1 trial: Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 28, 2012
P1, N=12, Recruiting, Sponsor: Life Extension Foundation Inc.
- || Enrollment change: A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects (clinicaltrials.gov) - Oct 25, 2012
P1, N=60, Completed, Sponsor: Eisai Inc.
Recruiting --> Terminated; Lack of Efficacy N=91 --> 60
- ||| Trial completion: A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects (clinicaltrials.gov) - Oct 25, 2012
P1, N=60, Completed, Sponsor: Eisai Inc.
N=91 --> 60 Recruiting --> Completed
- ||||| New P2 trial: Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (clinicaltrials.gov) - Oct 24, 2012
P2, N=126, Recruiting, Sponsor: Purimed Co., Ltd.
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 24, 2012
P1, N=12, Recruiting, Sponsor: Life Extension Foundation Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: OPHELIE-COG: Pre-stroke Cognitive Status and Thrombolytic Therapy (clinicaltrials.gov) - Oct 22, 2012
P=N/A, N=1040, Recruiting, Sponsor: University Hospital, Lille
- ||||| PF-05212377 / Pfizer
New P2 trial: Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil (clinicaltrials.gov) - Oct 21, 2012
P2, N=342, Recruiting, Sponsor: Pfizer
- Trial completion: The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort - (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=326, Completed, Sponsor: Holdsworth House Medical Practice
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=248, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI) (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=181, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Completed
- Trial withdrawal, MRI: Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change, MRI: Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Withdrawn N=110 --> 0
- | rivastigmine / Generic mfg.
Biomarker, Trial completion: Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease (clinicaltrials.gov) - Oct 16, 2012
P4, N=12, Completed, Sponsor: North Shore Long Island Jewish Health System
N=110 --> 0 Active, not recruiting --> Completed